Advanced Search

Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine 2003 December;47(4) > The Quarterly Journal of Nuclear Medicine 2003 December;47(4):337-48

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUETHE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging

A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413

Frequency: Quarterly

ISSN 1824-4785

Online ISSN 1827-1936

 

The Quarterly Journal of Nuclear Medicine 2003 December;47(4):337-48

USE OF RADIOLABELLED PEPTIDES FOR SCINTIGRAPHY IN NON-ONCOLOGIC DISEASES 

Imaging cell death in vivo

Blankenberg F. 1, Mari C. 1, Strauss H. W. 2

1 Department of Radiology Stanford University School of Medicine, Stanford, ca, USA
2 Section of Nuclear Medicine Memorial Sloan Kettering Cancer Center New York, ny, USA

A tech­nique to ­image pro­grammed ­cell ­death ­would be use­ful ­both in clin­i­cal ­care and in ­drug devel­op­ment. The ­most wide­ly stud­ied ­agent for the in ­vivo ­study of apop­to­sis is radio­lab­eled annex­in V, an endog­e­nous pro­tein ­labeled ­with tech­nec­tium-99m, now under­go­ing clin­i­cal ­trials in ­both Europe and the United States. While annex­in V has ­been stud­ied exten­sive­ly in ­humans the pre­cise mech­a­nism(s) of ­uptake ­this ­agent in ­vivo is ­unclear and ­needs fur­ther ­study. Other ­agents are ­also ­under devel­op­ment, includ­ing radio­lab­eled ­forms of Z-VAD.fmk, a ­potent inhib­i­tor of the enzy­mat­ic cas­cade inti­mate­ly asso­ciat­ed ­with apop­to­sis. In addi­tion oth­er tech­nol­o­gies, ­such as dif­fu­sion weight­ed mag­net­ic res­o­nance imag­ing and mag­net­ic res­o­nance imag­ing ­with con­trast ­agents, ­such as ­small par­a­mag­net­ic ­iron ­oxide par­ti­cles coat­ed ­with pep­tides ­have ­also ­been advo­cat­ed as meth­ods to mon­i­tor apop­tot­ic ­cell ­death. The poten­tial appli­ca­tions of imag­ing apop­to­sis as a mark­er of ear­ly ­response to ther­a­py in can­cer, ­acute cere­bral and myo­car­dial ischem­ic inju­ry and infarc­tion, ­immune medi­at­ed inflam­ma­to­ry dis­ease and trans­plant rejec­tion are ­reviewed.

language: English


FULL TEXT  REPRINTS

top of page